SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.100
-0.020 (-0.94%)
Aug 28, 2025, 4:00 PM - Market closed

SAB Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
0.111.322.2423.960.8855.24
Upgrade
Revenue Growth (YoY)
-95.87%-40.94%-90.63%-60.73%10.21%1504.91%
Upgrade
Cost of Revenue
30.1430.2516.5236.4457.1827.91
Upgrade
Gross Profit
-30.02-28.93-14.28-12.533.6927.33
Upgrade
Selling, General & Admin
11.813.9823.816.3817.096.77
Upgrade
Operating Expenses
11.813.9823.816.3817.096.77
Upgrade
Operating Income
-41.82-42.91-38.08-28.92-13.3920.56
Upgrade
Interest Expense
-0.28-0.32-0.32-0.3-0.29-0.47
Upgrade
Interest & Investment Income
0.491.290.580.070.020.03
Upgrade
Other Non Operating Income (Expenses)
4.537.81-4.3910.38-4.150
Upgrade
EBT Excluding Unusual Items
-37.08-34.13-42.19-18.76-17.8120.12
Upgrade
Gain (Loss) on Sale of Investments
0.030.03----
Upgrade
Gain (Loss) on Sale of Assets
---0.02--
Upgrade
Other Unusual Items
---0.030.67-
Upgrade
Pretax Income
-37.06-34.11-42.19-18.72-17.1420.12
Upgrade
Income Tax Expense
---0.03--
Upgrade
Net Income
-37.06-34.11-42.19-18.74-17.1420.12
Upgrade
Net Income to Common
-37.06-34.11-42.19-18.74-17.1420.12
Upgrade
Shares Outstanding (Basic)
996433
Upgrade
Shares Outstanding (Diluted)
996433
Upgrade
Shares Change (YoY)
21.75%67.74%26.86%59.20%1.21%-23.30%
Upgrade
EPS (Basic)
-3.99-3.68-7.64-4.31-6.277.92
Upgrade
EPS (Diluted)
-3.99-3.68-7.64-4.31-6.307.40
Upgrade
Free Cash Flow
-30.93-34.63-25.32-25.63-8.96-2.73
Upgrade
Free Cash Flow Per Share
-3.33-3.74-4.58-5.89-3.28-1.01
Upgrade
Gross Margin
----52.44%6.07%49.48%
Upgrade
Operating Margin
-36463.03%-3244.87%-1700.56%-120.97%-22.00%37.21%
Upgrade
Profit Margin
-32306.71%-2579.03%-1884.50%-78.40%-28.16%36.42%
Upgrade
Free Cash Flow Margin
-26965.30%-2618.65%-1130.71%-107.20%-14.71%-4.94%
Upgrade
EBITDA
-38.52-38.12-34.33-25.63-11.920.94
Upgrade
EBITDA Margin
----107.20%-19.55%37.91%
Upgrade
D&A For EBITDA
3.314.793.753.291.490.38
Upgrade
EBIT
-41.82-42.91-38.08-28.92-13.3920.56
Upgrade
EBIT Margin
----120.97%-22.00%37.21%
Upgrade
Revenue as Reported
0.111.322.2423.960.8855.24
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q